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Abstract
Background: Rhabdomyosarcoma is a common malignancy in children. There are two major
types of rhabdomyosarcomas, the embryonal and the alveolar, differing in cytogenetic and
morphologic features. The alveolar type of rhabdomyosarcoma is frequently associated with
chromosome translocation t(2, 13) and poor clinical prognosis. Pathogenesis of
rhabdomyosarcoma remains obscure, and especially it occurs in the location where skeletal muscle
is absent. We report here that there is a high frequency of association of rhabdomyosarcoma with
ataxia telangiectasia mutated (ATM) gene mutation/deletion.
Result: Totally 17 cases of rhabdomyosarcoma specimens were studied by immunohistochemical
or immunofluorescent staining with ATM antibody and revealed that 7 of the 17 cases were
negative for ATM expression (41%). Further analyses of rhabdomyosarcoma cell lines with RT-PCR
revealed that in Rh30 cells, an alveolar rhabdomyosarcoma cell line, there are three separate
deletions/mutations of the ATM mRNA. Western blotting analysis of the Rh30 cellular extract with
anti-ATM antibody showed that there is an aberrant form of ATM protein within the Rh30 cells
that are smaller than normal control.
Conclusion:  These results suggest a link of ATM gene deletion/mutation with
rhabdomyosarcoma, and since ATM kinase is a crucial regulatory protein in DNA damage repair
signaling pathway, and ATM deletion/mutation may contribute to pathogenesis of
rhabdomyosarcoma.
Background
Rhabdomyosarcoma is a malignant neoplasm of skeletal
muscle, and is one of the most common soft tissue malig-
nancies in the children and adolescent population. His-
topathologically rhabdomyosarcoma can be divided into
two major subtypes, embryonal rhabdomyosarcoma rep-
resenting about 80% of the clinical cases, and alveolar
rhabdomyosarcoma representing about 20% of the total
cases [1,2]. Extensive cytogenetic studies showed that the
embryonal rhabdomyosarcomas are generally associated
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with loss of heterozygosity (LOH) for multiple closely
linked loci at chromosomal 11p15.5, suggesting inactiva-
tion of one or more tumor-suppressor gene(s) in this re-
gion [2,3]. But the gene involved in this region has yet to
be identified. Many other associated mutation or amplifi-
cation of oncogenes, tumor suppressor genes including
p53, K-ras, N-ras and N-myc, etc. are frequently seen, but
the roles of these gene mutations/amplifications in patho-
genesis of the tumor remain largely unclear [4];[5]. The al-
veolar subtype of rhabdomyosarcoma, however, is
consistently associated with two common chromosomal
translocations. Most cases of alveolar rhabdomyosarcoma
are associated with a chromosomal translocation t(2; 13)
(q35; q14), and less commonly with t(1; 13)(p36; q14)
[6–9]. The t(2; 13) translocation results in fusion of a por-
tion of the Pax3 gene to a portion of the FKHR gene, lead-
ing to formation of fusion protein Pax3-FKHR. Pax3 gene
encodes a transcriptional factor important in early devel-
opment program, while FKHR gene encodes another ge-
neric transcriptional factor that is widely expressed in
mammalian tissues. The t(1; 13) translocation results in
formation of Pax7-FKHR. Both Pax3-FKHR and Pax7-
FKHR were shown to possess more potent transcriptional
activity than its original forms Pax3 and Pax7 [10,11].
How the chimeric fusion proteins contribute to pathogen-
esis of rhabdomyosarcoma remains unclear.
Ataxia telangiectasia mutated gene (ATM) is a newly iden-
tified member of PI3 kinase family that is mutated in hu-
man autosomal recessive disease, ataxia telangiectasia
(AT) [12,13]. ATM gene is large, spanning about 150 kbs
of genomic DNA, and is located on chromosome 11q22-
23. In response to DNA damage agents such as ionizing ir-
radiation and chemical agent cisplatin, ATM kinase is ac-
tivated, leading to a cascade of kinase reactions regulating
cell cycle, apoptosis, and DNA damage repair [14,15].
Many downstream target molecules of ATM kinase were
so far identified. These target proteins include the c-Abl ty-
rosine kinase, the p53 tumor suppressor, the Chk1 and
Chk2 serine/threoine kinase, the p34 subunit of replica-
tion protein A (RPA), Chk1 serine/threoine kinase and
NBS1 kinase which is mutated in human autosomal reces-
sive disease Nijmegan breakage syndrome [16–23]. Clini-
cal characteristics of AT patients include hypersensitivity
to irradiation, thymic dysplasia, immune defects and
higher tendency to develop malignant tumor, suggesting
that ATM function is critical in DNA damage repair and
tumor suppression. However, up to date, AT patients are
not known to develop rhabdomyosarcoma.
In this study, we report an association of human rhab-
domyosarcoma with deletion/mutation of ATM gene.
This is the first report so far of ATM gene associated with
solid malignancy except for the mantle cell lymphoma, a
malignant tumor in lymphoid origin. The association of
ATM gene mutation/deletion with rhabdomyosarcoma
suggests a link of ATM gene with cancer risk, and ATM ki-
nase may contribute to pathogenesis of
rhabdomyosarcoma.
Results
Totally 17 patients specimen were retrieved from the ar-
chived tissue blocks. The clinical characteristics of these
patients were listed as in Table 1. Some patient's clinical
information was not available at the time of the study.
These patients all carried clinical histopathological diag-
noses of rhabdomyosarcoma (embryonal or alveolar
type), and showed immunostaining positivity for myo-
genin, a specific skeletal muscle marker. Immunofluores-
cent or immunohistochemical staining with anti-ATM
antibody was performed on the total of 17 specimens, and
7 of the 17 rhabdomyosarcomas were negative for ATM
protein (41%) (see Table 1). Totally 10 of the 17 were pos-
itive for ATM kinase (59%). ATM protein was predomi-
nantly located in cytoplasm in the tumor sections and
interestingly, predominantly seen in the nuclei in the
rhabdomyosarcoma cell line, as those seen with myoD
staining (RD cells) (Fig 1 and 2). There is no difference in
staining pattern in regard to the subtypes of the rhab-
domyosarcomas, namely embryonal or alveolar subtypes.
It is surprising to note that 7 of the17 (41%) rhabdomy-
osarcoma specimens stained negatively for the presence of
ATM protein. Under the normal condition, ATM expres-
sion is ubiquitous. To further confirm the immunostain-
ing results, two different approaches were taken. One was
to see if the ATM mRNA is properly transcribed, and an-
other is to directly see the ATM protein itself by Western
blotting analysis from the tumors and compare with the
normal form. Due to the limited resource of the fresh tu-
mor samples, we turned to the cell culture system and
used the well-established rhabdomyosarcoma cell lines.
First, we designed eight pairs of oligonucleotide primers
encompassing the almost entire coding sequence of ATM
mRNA based on the published cDNA sequence (Genbank
accession number U33841)[24](Table 2). The primer de-
signing strategy is shown in Fig 3. ATM mRNA is approxi-
mately 9.4 kbs in length and contains multiple protein
binding domains for its kinase activity and interaction
with other cellular proteins (Fig 3). We used reverse tran-
scription-PCR method to analyze five different rhab-
domyosarcoma cell lines, RD cells (embryonal), Rh28,
Rh30 (alveolar), Rh3, Rh4, and mouse normal myoblast
C2C12 cells. The human foreskin fibroblasts were used as
the control cells. The mRNA was isolated from these cells
and used for RT-PCR assays. As shown in Fig 4, in normal
fibroblasts, RD cells, Rh28 cells, the amplified DNA frag-
ments were identical in regard to the lengths in comparing
with the control fibroblasts, whereas in Rh30 cells, two
fragments in #1 and #7 lanes (0.94 kbs in Lane #1, and 1.3Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/2
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kbs in Lane #7) were absent, and in lane #6, the fragment
amplified was approximately 200 bps smaller than that
seen in the fibroblasts and other rhabdomyosarcoma cells
(Fig 4). The combined length of missing DNA sequence is
estimated 2.4 kb (fragment #1, plus fragment #7, and ad-
ditional 200 bps in lane #6).
The next question is whether ATM protein is normally
translated from ATM mRNA and expressed in the rhab-
domyosarcoma cells. We analyzed the ATM protein in dif-
ferent cell lines. In human Hela cells and human normal
foreskin fibroblasts, the ATM was estimated to be 360 kD,
consistent with the results previously described[12,13]. In
three rhabdomyosarcoma cell lines (RD, Rh28 and
RH30), there was one aberrant form of ATM protein
(~260 kD) that was significantly smaller than that seen in
the normal fibroblasts and the Hela cells (Fig 5). The lev-
els of ATM expression in these three rhabdomyosarcoma
cell lines are not identical, and Rh30 cells seemed to ex-
press less ATM than the other two Rhabdomyosarcoma
cells. The murine ATM proteins from C2C12 and 10T 1/2
cells were significantly different in size and there appeared
to be two species of ATM proteins in murine cells.
Discussion
ATM gene is a member of PI3 kinase family. ATM kinase
is critical in DNA damage signaling pathway. In response
to DNA damage induced by ionizing radiation or chemi-
cal agents such as cisplatin, ATM kinase is activated and
phosphorylates a number of downstream regulatory pro-
teins important for cell cycle arrest, growth control, apop-
tosis and DNA repair [25–28]. AT patients are known to
Figure 1
Immunostaining of rhabdomyosarcoma cases. Immunofluorescent staining of five representative cases with anti-ATM 
antibody. PT: patient. The secondary antibody was conjugated to rhodamine. The photograph was taken at 200X using Zeiss 
UV fluorescent microscope.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/2
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Figure 2
Immunoperoxidase staining of the rhabdomyosarcoma tumor with a negative control. Upper panel represents 
immunoperoxidase staining of a patient's tumor. The positive staining signals were seen in cytoplasm. The photograph were 
taken at the magnification of 400X. Lower panel represents immunofluorescent staining of the cultured RD cells with antibod-
ies against ATM and MyoD. The signals were seen in the nuclei. The photograph was taken at 400X.
Table 1: RMS Patients and immunostaining profiles
Case 1 15/M. Paratesticular embryona ATM (-)
Case 2 19/M. Prostate/bone marrow alveolar ATM (+) weakly/cytoplasmic
Case 3 4/M Salivary gland embryona ATM (+)/Cytopiasmic
Case 4 3/M. Pelvis embryona ATM (+)/Cytoplasmic
Case 5 4/M. Paraspinal alveolar ATM (+) weakly/Cytoplasmic
Case 6 4/M. Skull base embryona: ATM (+)/Cytoplasmic
Case 7 6/M. Abdoman alveolar ATM (-)
Case 8 unknown unknown alveolar ATM (+)/Cytoplasmic
Case 9 unknown unknown embryona ATM (+)/Cytoplasmic
Case 10 unknown unknown embryona ATM (+)/Cytoplasmic
Case 11 unknown unknown embryona ATM (-)
Case 12 unknown unknown unknown ATM (-)
Case 13 unknown unknown unknown ATM (-)
Case 14 unknown unknown lunknown ATM (-) 1
Case 15 unknown unknown unknown ATM (-) 1
Case 16 unknown unknown unknown ATM (+)/Cytoplasmic
Case 17 unknown unknown unknown ATM (+)/CytoplasmicMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/2
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Figure 3
Diagrammatic representation of the ATM protein structure and the RT-PCR strategy. The primer pairs were 
designed as shown and as listed in Table 2.
Figure 4
RT-PCR amplification of ATM mRNA in the different cells using the primer pairs listed in Table2. Human fore-
skin fibroblasts, human rhabdomyosarcoma cell lines were cultured and the total RNAs were isolated from the cultured cells. 
The RT-PCR was performed using the total RNA from the cells, and the PCR products were separated on 1% agarose gel and 
visualized by staining with ethidium bromide. The lengths of the PCR products were compared with each cell line used.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/2
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be predisposed to a variety of cancers, and the fibroblasts
of AT patients are hypersensitive to ionizing radiation
[29]. Although many reports showed the association of
ATM mutation with risk of a number of different human
malignancies, including prostate cancer, breast cancer,
ovarian cancer, B-cell chronic lymphocytic leukemia and
mantle cell lymphoma, the underlying molecular mecha-
nism by which ATM gene causes these changes are not
well understood [30–35]. There is so far no study showing
the association of ATM gene with any solid tumor. There
is enormous epidemiological interest in establishing the
link of ATM gene abnormality with cancer risk, since the
percentage of the ATM heterozygotes is high, and estimat-
ed to represent 1.5% of total population.
We studied the immunostaining characteristics of ATM
protein in clinical rhabdomyosarcoma cases and found
that a significantly high number of cases lacked the proper
ATM gene product (41% in 17 cases). The clinical signifi-
cance of this finding is unclear at this point. There is high
percentage of clinical rhabdomyosarcoma cases associat-
ed with p53 gene mutation/deletion. The p53 mutant
mice tend to develop rhabdomyosarcoma [29]. P53 is a
tumor suppressor regulating cell cycle control and
apoptosis, and p53 is one of the many downstream targets
of ATM kinase[25,27]. ATM phosphorylate p53 at Serine
15 in response to DNA damage agents [17]. It is unknown
how the mutated ATM contributes to pathogenesis of
rhabdomyosarcoma in the presence of the mutated p53.
In fact, the rhabdomyosarcoma cells Rh30 is known to
have p53 mutation, and is also positive for t(2; 13) chro-
mosomal translocation [11]. Further investigations are
needed to address these important questions.
The finding of ATM protein predominantly present in the
cytoplasm, but not the nucleus of the tumor sections sug-
gests a different role of ATM in the tumor cells. In the tu-
mor cell lines, the ATM protein is present predominantly
in the nucleus. The underlying significance of this finding
is unclear. Presumably ATM protein in the cytoplasm may
function differently in the tumor cells in vivo from that in
the nucleus seen in the cell culture.
The murine ATM was found significantly different in size,
although the ATM knockout mice recapitulate the pheno-
typic features of A-T patients [36]. This species difference
may be important in interpreting the data from human
cells and from murine cells.
Methods
Immunohistochemical and immunofluorescent staining
Human rhabdomyosarcoma tumor specimens were ob-
tained from the Department of Pathology, the Children's
Hospital San Diego. All human tissues were formalin
fixed, paraffin embedded and were previously used for di-
agnostic purposes. Current study was approved by the In-
stitutional Review Board at University of California, San
Diego (IRB). The specimens were sectioned at 5 micron in
thickness, and used for immunohistochemical staining
with ATM antibody as described [18]. Briefly, the sections
were de-paraffinized in xylene solution, de-hydrated and
rehydrated in 100%, 90% and 70% alcohol. The speci-
mens were immersed in Antigen Retrieval solution (com-
mercially available from Dako Corp. CA) at 90°C for 30
minutes to unmask the antigen followed by incubation
with primary antibody against ATM protein at 4°C over-
night. The primary anti-ATM antibody was kindly
provided by Dr. Gately and as described previously [18].
Table 2: Oligonucleotide primers for RT-PCR amplifications
Primer Oligonucleotide sequence (5' – 3')
1A (exon 36) CTT CAG TGG ACC TTC ATA ATG C
1B (exon 43) CCA TAC AAA CTA TCT GGC TCC
2A (exon 29) CAG AGA TTG TGG TGG AGT TAT TG
2B (exon 36) GCA TTA TGA AGG TCC ACT GAA G
3A (exon 42/43) CTG GAA TAA GTT TAC AGG ATC TTC
3B (exon 51) GAT GAT TTC ATG TAG TTT TCA ATT C
4A (exon 56) AAG ATG TTG TTG TCC CTA CTA TG
4B (exon 65) AAG GCT GAA TGA AAG GGT AAT TC
5A (exon 51) GAT GGA GAA AGT AGT GAT GAG C
5B (exon 57) AGT CAC CAG ATT TCC ATA TTC TC
6A (exon 22) CTA GGT CAA AGC AAT ATG GAC TC
6B (exon 30) CAT GCG ATG GAA AAT GAG GTG
7A (exon 13) TGC CTC CAA TTC TTC ACA G
7B (exon 22/23) CCT CTC CTT TGT TAG ATG CC
8A (exon 3) AGG CAT ACA TCA CAA TTT GG
8B (exon 12) TTG CTC AGA ACT TAT ACC ACGMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/2
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The second antibody was either immuno-peroxidase con-
jugated for immunochemical stains or Cy3 conjugated
anti-rabbit IgG for immunofluorescent stains (Molecular
Probes, OR). For immunofluorescent staining for the
tumor cell lines, the tumor cells were cultured on the glass
coverslips, fixed by 4% paraformaldehyde and stained
with primary antibody against ATM and MyoD as de-
scribed [37].
Cell culture, RNA isolation, reverse transcription and PCR
Rhabdomyosarcoma cell lines, such as Rh3, Rh4, Rh 28,
RH30 and RD cells were obtained from Dr. Karen Arden,
Ludwig Institute of Cancer Research at UCSD. The tumor
cell lines were cultured and maintained as described [37].
The total RNA was isolated from the cultured cells using
Trizol RNA isolation kit (GBCOL-BRL, Besthesda, MD).
The cDNA synthesis was performed using the cDNA syn-
thesis kit (Supersccript, GBCOL-BRL) using random hex-
amer and oligo-d(T) primers following the instruction
from the manufacturer. The total cDNA was directly used
Figure 5
Western blotting of ATM protein in the cultured cells. The whole cell lysates were separated on 4.5% SDS-PAGE and 
the ATM protein was detected by using anti-ATM antibody. Lane 1: Hela cells, lane 2: RD cells, lane3: Rh28 cells, lane 4: Rh30 
cells, lane: 5, normal human foreskin fibroblast cells, lane 6, C2C12 mouse myoblasts, Lane 7. Mouse 10T1/2 fibroblasts.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/2
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as templates for PCR amplification for ATM gene using the
primer pairs in Table 2. The primer sequences were based
on the ATM sequence (Genbank accession number
U33841), and were described for mantle cell lymphoma
with slight modification [24]. The primers were synthe-
sized by Sigma-Genosys (Woodlands, Texas). The PCR
products were electrophoresed in 1% agarose gel and vis-
ualized using ethidium bromide staining.
Western blotting of ATM protein
The rhabdomyosarcoma cells are cultured and main-
tained as described [37]. The cellular proteins were pre-
pared, separated on 4% polyacrylamide gel and
transferred onto nitrocellulose membrane. The immobi-
lized proteins were incubated with anti-ATM anti-
body[18]. The proteins of interest were detected by
enhanced immunochemiluminescence kit from Amer-
sham Life Sciences [37].
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